COMMUNIQUÉS West-GlobeNewswire

-
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
21/04/2025 -
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
21/04/2025 -
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
21/04/2025 -
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
21/04/2025 -
Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors
21/04/2025 -
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
21/04/2025 -
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
21/04/2025 -
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
21/04/2025 -
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
21/04/2025 -
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
21/04/2025 -
BioStem Technologies to Present at the Centri Capital Conference
21/04/2025 -
Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations
21/04/2025 -
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
21/04/2025 -
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
21/04/2025 -
BioCryst to Report First Quarter 2025 Financial Results on May 5
21/04/2025 -
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
21/04/2025 -
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
21/04/2025 -
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
21/04/2025 -
Apellis Announces Craig Wheeler to Join the Board of Directors
21/04/2025
Pages